F.H. van Bruggen

Faculteit Medische Wetenschappen/UMCG

Telefoon:

E-mail:

f.h.van.bruggen umcg.nl

ORCID Research Portal

Publicaties

Comment on Chwal et al. On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty. J. Clin. Med. 2024, 13, 7667

van Bruggen, F. H. & Luijendijk, H. J., apr.-2025, In: Journal of Clinical Medicine. 14, 8, 2 blz., 2559.

Onderzoeksoutput: Comment/Letter to the editor › › peer review

Is Targeting LDL-C Levels Below 70 mg/dL Beneficial for Cardiovascular and Overall Health? A Critical Examination of the Evidence

van Bruggen, F. H. & Diamond, D. M., mei-2025, In: Journal of Clinical Medicine. 14, 10, 15 blz., 3569.

Onderzoeksoutput: Review article › peer review

Rethinking Cholesterol-lowering Medication: Exploring Disease Delay, Serious Adverse Events, and Room for Discontinuation

van Bruggen, F., 2025, [Groningen]: University of Groningen. 225 blz.

Onderzoeksoutput

Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal

van Bruggen, F. H. & Luijendijk, H. J., 2025, In: Frontiers in cardiovascular medicine. 12, 4 blz., 1564432.

Onderzoeksoutput: Article › › peer review

Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study

van Bruggen, F. H., Zuidema, S. U. & Luijendijk, H. J., 22-jun.-2024, In: BMC Medical Research Methodology. 24, 13 blz., 137.

Onderzoeksoutput: Article › › peer review

Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects

van Bruggen, F. H., de Haas, E. C., Zuidema, S. U. & Luijendijk, H. J., nov.-2024, In: American journal of cardiovascular drugs. 24, blz. 743-752 10 blz.

Onderzoeksoutput: Review article › peer review

Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER

van Bruggen, F. H. & Luijendijk, H. J., jan.-2022, In: American journal of cardiovascular drugs. 22, 1, blz. 5-8 4 blz.

Onderzoeksoutput: Comment/Letter to the editor › › peer review

Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U. & Luijendijk, H. J., 21-jan.-2021, In: Expert Review of Clinical Pharmacology. 14, 2, 2 blz.

Onderzoeksoutput: Comment/Letter to the editor › › peer review

Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review

van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U. & Luijendijk, H. J., 2020, In: Expert Review of Clinical Pharmacology. 13, 7, blz. 787-796 11 blz.

Onderzoeksoutput: Article › › peer review

LDL: hoe lager, hoe duurder

van Bruggen, F., 1-sep.-2019, In: Huisarts en Wetenschap. 62, 9, blz. 34-35 2 blz.

Onderzoeksoutput: Article › › peer review

Alle (13) publicaties

Bekijk volledig onderzoeksprofiel